Trial Profile
A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Trebananib (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms TRINOVA-1
- Sponsors Amgen; Takeda
- 19 Dec 2016 This trial has been Discontinued in Czech Republic according to European Clinical Trials Database record.
- 14 Dec 2016 Status changed from active, no longer recruiting to completed.
- 18 Aug 2016 Results assessing overall survival in the intent-to-treat population and of a subgroup analysis published in the Gynecologic Oncology